# IL-17 Blockade to Decrease irAEs (REPLAY)

> **NCT07237594** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Duke University** · enrollment: 4 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Secukinumab Injection

## Key facts

- **NCT ID:** NCT07237594
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07237594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07237594, "IL-17 Blockade to Decrease irAEs (REPLAY)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07237594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*